Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MolDX lists Signatera for recurrence testing in non-small cell lung cancer

The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for the diagnosis of recurrence or relapse in patients with a personal history of non-small cell lung cancer.

CMS MolDX